ARD-2128

CAS No. 2222111-87-5

ARD-2128 ( —— )

Catalog No. M28233 CAS No. 2222111-87-5

ARD-2128 is a highly potent, orally bioavailable PROTAC androgen receptor (AR) degrader. ARD-2128 effectively reduces AR protein, suppresses AR-regulated genes in tumor tissues, and inhibits growth of tumor without signs of toxicity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 308 Get Quote
5MG 520 Get Quote
10MG 750 Get Quote
25MG 1143 Get Quote
50MG 1521 Get Quote
100MG 2061 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    ARD-2128
  • Note
    Research use only, not for human use.
  • Brief Description
    ARD-2128 is a highly potent, orally bioavailable PROTAC androgen receptor (AR) degrader. ARD-2128 effectively reduces AR protein, suppresses AR-regulated genes in tumor tissues, and inhibits growth of tumor without signs of toxicity.
  • Description
    ARD-2128 is a highly potent, orally bioavailable PROTAC androgen receptor (AR) degrader. ARD-2128 effectively reduces AR protein, suppresses AR-regulated genes in tumor tissues, and inhibits growth of tumor without signs of toxicity. ARD-2128 has the potential for the research of the prostate cancer.(In Vitro):ARD-2128 is highly potent and effective in the inhibition of cell growth in the VCaP cell line and LNCaP cell line with the IC 50 values of 4 nM and 5 nM, respectively . ARD-2128 (1, 10, 100, and 1000 nM; 24 hours) effectively reduces the AR protein level by >50% at 1 nM and achieves the AR degradation of >90% at 10, 100, and 1000 nM, respectively, in VCaP cell . Cell Viability Assay Cell Line: VCaP cell Concentration: 1, 10, 100, and 1000 nM Incubation Time: 24 hours Result: Reduces the AR protein level and achieves the AR degradation.(In Vivo):ARD-2128 (20 mg/kg; p.o.; once) is effective in reducing the level of AR protein in mice after 24 hours . ARD-2128 (10-40 mg/kg; p.o.; daily for 21 days) shows antitumor activity in the VCaP xenograft model in mice . ARD-2128 (5mg/kg; p.o.) treatment shows the C max , AUC 0-t and t 1/2 values of 1304 ng/mL, 22361 ng h/mL and 18.8 hours, respectively . Animal Model: SCID mice Dosage: 20 mg/kg Administration: Oral Result: Reducing the level of AR protein in mice after 24 hours. Animal Model: SCID mice Dosage: 10, 20, and 40 mg/kg Administration: P.o.; daily for 21 days Result: Inhibits tumor growth by 46, 69, and 63%, respectively. Animal Model: Male ICR Mice Dosage: 5 mg/kg Administration: P.o. (Pharmacokinetic Analysis) Result: The C max , AUC 0-t and t 1/2 were 1304 ng/mL, 22361 ng h/mL and 18.8 hours, respectively.
  • Synonyms
    ——
  • Pathway
    Endocrinology/Hormones
  • Target
    Androgen Receptor (AR)
  • Recptor
    TNIK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2222111-87-5
  • Formula Weight
    820.4
  • Molecular Formula
    C45H50ClN7O6
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CC(C)([C@H](C1(C)C)NC(c(cc2)ccc2N2CCN(CC(CC3)CCN3c(cc3)cc(C(N4C(CCC(N5)=O)C5=O)=O)c3C4=O)CC2)=O)[C@H]1Oc(cc1)cc(Cl)c1C#N
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Shengyong Yang, Linli Li. Preparation of TNIK inhibitor compounds as antitumor agents. CN113773316A
molnova catalog
related products
  • JNJ63576253

    JNJ-63576253 is a Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).

  • EPI-001

    EPI-001 is a small molecule that blocks transactivation of the androgen Receptor (AR) NTD (IC50=6 uM).

  • Dehydroepiandrostero...

    Dehydroepiandrosterone acetate is a major C19 steroid produced by the adrenal cortex.